A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available | Zendy

Umberto Tirelli | Zendy; Antonino Carbone | Zendy; Raffaele Di Francia | Zendy; Massimiliano Berretta | Zendy

Open Access

A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available

Author(s) -

Umberto Tirelli,

Antonino Carbone,

Raffaele Di Francia,

Massimiliano Berretta

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2019.10.61

Subject(s) - medicine , neutropenia , biosimilar , filgrastim , chemotherapy , febrile neutropenia , intensive care medicine , limiting , oncology , mechanical engineering , engineering

Chemotherapy is still one of the main tools for treatment of pediatric and adult blood and solid tumors and is capable of cure some acute leukemia, some advanced lymphomas, advanced testicular cancers among others (1). However, the main side effects and limiting factors for its use is myelotoxicity, in particular neutropenia and eventual life threatening febrile neutropenia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research